SCHEMBL4376341

SCHEMBL4376341

Cc1cc(O)cc(=O)n1-c1c(F)cccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.42
POLB P06746 1/20 0.42
PDE7A Q13946 7/20 0.40
LMNA P02545 1/20 0.39
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
PDE7B Q9NP56 2/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
NOTUM Q6P988 2/20 0.39
APLNR P35414 1/20 0.35
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
THRB P10828 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4381208 0.83 ANPEP (0.45) MAPK14POLBLMNANOTUMAPLNR
SCHEMBL4390382 0.82 MAPK14 (0.43) MAPK14POLBLMNAL3MBTL1
SCHEMBL4378397 0.80 NOTUM (0.53) MAPK14POLBLMNANOTUM
SCHEMBL4384354 0.76 MAPK14 (0.53) MAPK14PDE7APDE4APDE4BPDE4C
SCHEMBL4384626 0.74 MAPK14 (0.52) MAPK14PDE7APDE4APDE4BPDE4C
SCHEMBL4389760 0.74 APLNR (0.54) MAPK14POLBAPLNRGAASMN1; SMN2
SCHEMBL4378657 0.73 MAPK14 (0.37) MAPK14POLB
SCHEMBL4381266 0.70 MAPK14 (0.65) MAPK14
SCHEMBL4389841 0.70 POLB (0.40) MAPK14POLBLMNANOTUMAPLNR
SCHEMBL24759473 0.69 POLB (0.36) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MAPK14 41/4885POLB 1610/4885PDE7A 245/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPK14 53/4885POLB 1676/4885PDE7A 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.